GH
BTAI icon

GAM Holding’s BioXcel Therapeutics BTAI Stock Holding History

GAM Holding’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-975
Closed -$453K – 314
2021
Q2 		$453K Hold
975
– – 0.02% 258
2021
Q1 		$673K Buy
+975
New +$784K 0.03% 251

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GAM Holding's BTAI Position: Q3 2021 in Review

GAM Holding sold out of BioXcel Therapeutics (BTAI) in Q3 2021, closing a stake of 975 shares — an estimated $453K sold.

GAM Holding first reported a position in BTAI in Q1 2021 and held it in 2 quarters. The position peaked at $673K in Q1 2021. 103 funds tracked by Wall St. Rank hold BTAI as of Q3 2021.

  • GAM Holding reported no remaining BioXcel Therapeutics position as of Q3 2021 after selling out during the quarter.
  • GAM Holding sold 975 BioXcel Therapeutics shares in Q3 2021, an estimated $453K.
  • GAM Holding first reported a position in BioXcel Therapeutics in Q1 2021 and held it in 2 quarters.
  • GAM Holding's BioXcel Therapeutics position peaked at $673K in Q1 2021.
  • 103 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2021.

Based on GAM Holding's 13F filing for Q3 2021, filed 12 Nov 2021.